Next Treatments
Back to Eczema

temtokibart

TypeInjection StagePhase 2 Latest updateFeb 12, 2026Phase 2 results posted

What stands out

New approach in eczema

  • Binds to IL-22 receptor, part of the docking point for the IL-22 signal
  • Injection every 2 weeks in trials
Derived from FDA substance registry · NCT05923099 · UniProt Q8N6P7 ·
11 US eczema labels (Cibinqo, Eucrisa, Adquey, Dupixent, Ebglyss, Nemluvio, Zoryve, Opzelura, Vtama, Adbry, Rinvoq)
· This is a summary of public records for informational purposes only. It is not medical advice.

Results

Trial: NCT05923099
Percent Change in EASI ScoreAfter 16 weeks

Lower scores mean less severe eczema.

Placebo Regimen52 people
42% lower
Dose Regimen 152 people
61% lower
Dose Regimen 253 people
57% lower
Dose Regimen 352 people
64% lower
Dose Regimen 453 people
51% lower
040%80%
19points
more of a drop on average on Dose Regimen 1 than on placebo.
The sponsor’s 95% confidence range is 5 to 34 points more.
15points
more of a drop on average on Dose Regimen 2 than on placebo.
The sponsor’s 95% confidence range is 1 to 30 points more.
23points
more of a drop on average on Dose Regimen 3 than on placebo.
The sponsor’s 95% confidence range is 8 to 37 points more.
10points
more of a drop on average on Dose Regimen 4 than on placebo.
The sponsor’s 95% confidence range is 5 points less to 24 more.
NCT05923099 · Ages 18–75 · Results posted Feb 2026 · This is a summary of trial data for informational purposes only. It is not medical advice.
What is EASI?
  • EASI stands for Eczema Area and Severity Index.
  • The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of atopic dermatitis. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe, and/or more extensive condition.As this trial registered it · NCT05923099
Why this trial?

Of temtokibart’s 3 trials with posted results, NCT05923099 is shown first: of the trials that compared the drug with placebo on a result this page charts, it tested more doses (4). We rank those trials by whether they set out to measure skin clearing, whether they tested the drug on its own, their phase, whether they were randomised, whether they included adults, whether they ran in the US, how many doses they tested, how many US sites they had, their size, and then how recently they finished.

All 3 temtokibart trials
PostedTrialPhaseAgesPeople
Feb 2026NCT05923099 Shown abovePhase 218–75262
Feb 2025NCT05470114Phase 218–6413
Jul 2023NCT04922021Phase 218–6458

History

Earliest recorded event: May 7, 2018. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Feb 12, 2026Phase 2 results postedA Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT05923099
  • Apr 9, 2025Phase 2 trial completedA Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT05923099
  • Feb 14, 2025Phase 2 results postedA Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD ClinicalTrials.gov NCT05470114
  • Dec 11, 2024Phase 2 main data collectedA Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT05923099
  • Oct 9, 2023Phase 2 trial completedA Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD ClinicalTrials.gov NCT05470114
  • Sep 20, 2023Phase 2 trial startedA Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT05923099
  • Jul 24, 2023Phase 2 results postedAn Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis. ClinicalTrials.gov NCT04922021
  • Jun 7, 2023Phase 2 main data collectedA Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD ClinicalTrials.gov NCT05470114
  • Sep 26, 2022Phase 2 trial completedAn Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis. ClinicalTrials.gov NCT04922021
  • Jun 28, 2022Phase 1 trial completedA Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects ClinicalTrials.gov NCT05099133
  • Jun 2, 2022Phase 2 main data collectedAn Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis. ClinicalTrials.gov NCT04922021
  • May 19, 2022Phase 2 trial startedA Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD ClinicalTrials.gov NCT05470114
  • Nov 3, 2021Phase 1 trial startedA Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects ClinicalTrials.gov NCT05099133
  • Jul 14, 2021Phase 2 trial startedAn Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis. ClinicalTrials.gov NCT04922021
  • Mar 2, 2021Phase 1 trial completedSafety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis ClinicalTrials.gov NCT03514511
  • May 7, 2018Phase 1 trial startedSafety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis ClinicalTrials.gov NCT03514511

Sources

Trials